DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on July 16, 2007; DOI: 10.1124/dmd.107.014969


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.014969v1
35/10/1873    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ando, T.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ando, T.
Right arrow Articles by Sugiyama, Y.


Received for publication January 23, 2007.
Revised July 10, 2007.
Accepted for publication July 12, 2007.

Involvement of Breast Cancer Resistance Protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones

Tomohiro Ando 1, Hiroyuki Kusuhara 1, Gracia Merino 2, Ana I. Alvarez 2, Alfred H Schinkel 3, Yuichi Sugiyama 1*

1 The University of Tokyo 2 University of Leon 3 The Netherlands Cancer Institute

* Address correspondence to: E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp

Abstract

Fluoroquinolones are one of the effective antibiotics for the treatment of bile duct infections. It has been shown that the biliary excretion of grepafloxacin is partly accounted for by multidrug resistance associated protein 2 (MRP2/ABCC2), whereas neither MRP2 nor P-glycoprotein is involved in the biliary excretion of ulifloxacin. In the present study, we examined the involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion of fluoroquinolones (grepafloxaxcin, ulifloxacin, ciprofloxacin and ofloxacin). In MDCK II expressing human BCRP or mouse Bcrp, the basal-to-apical transport of grepafloxacin and ulifloxacin was greater than that of the mock control, which was inhibited by a BCRP inhibitor, Ko143. Plasma and bile concentrations of fluoroquinolones were determined in wild type and Bcrp (-/-) mice following intravenous bolus injection. The cumulative biliary excretion of fluoroquinolones was significantly reduced in Bcrp (-/-) mice, resulting in a reduction of the biliary excretion clearances to 50, 16, 40 and 36% of the control values, for ciprofloxacin, grepafloxacin, ofloxacin and ulifloxacin, respectively. Preinfusion of sulfobromophthalein significantly inhibited the biliary excretion of grepafloxacin in Bcrp (-/-) mice. There was no change in the tissue-to-plasma concentration ratios of fluoroquinolones in the liver or brain, while those in the kidney were increased 3.6- and 1.5-fold for ciprofloxacin and grepafloxacin, respectively, in Bcrp (-/-) mice, but were unchanged for ofloxacin and ulifloxacin. The present study shows that BCRP mediates the biliary excretion of fluoroquinolones, and suggests that it is also involved in the tubular secretion of ciprofloxacin and grepafloxacin.


Key words: ABC transporters, drug clearance, drug transport, hepatobiliary transport, membrane transport





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.